Erythrohydrobupropion

Erythrohydrobupropion is a major active metabolite of the antidepressant and smoking cessation drug bupropion. It is formed from bupropion by the enzyme CYP2B6 in the liver. Erythrohydrobupropion is believed to contribute to the clinical effects of bupropion due to its similar pharmacology.

Pharmacology

Erythrohydrobupropion acts as a norepinephrine-dopamine reuptake inhibitor (NDRI) and to a lesser extent as a nicotinic acetylcholine receptor antagonist, similarly to bupropion. However, its potency at the latter target is significantly lower than that of bupropion, which may explain the relatively small contribution of erythrohydrobupropion to the overall clinical effects of the drug.

Pharmacokinetics

Erythrohydrobupropion is formed from bupropion by the enzyme CYP2B6 in the liver. It has a longer half-life than bupropion, which allows it to maintain therapeutic levels in the body for a longer period of time. This is one of the reasons why bupropion is typically administered once or twice daily.

Clinical significance

Erythrohydrobupropion is believed to contribute to the clinical effects of bupropion due to its similar pharmacology. However, its exact role in the therapeutic effects of the drug is not fully understood and is the subject of ongoing research.

See also

• Bupropion
• Hydroxybupropion
• Threohydrobupropion

References

Erythrohydrobupropion Resources
Latest articles Most recent articles Ongoing trials	Wikipedia